| Identification | Back Directory | [Name]
TQ05310 | [CAS]
2071196-10-4 | [Synonyms]
TQ05310
1,3,5-Triazine-2,4-diamine, N2-(1,1-dimethylethoxy)-N4-[2-(trifluoromethyl)-4-pyridinyl]-6-[6-(trifluoromethyl)-2-pyridinyl]- | [Molecular Formula]
C19H17F6N7O | [MOL File]
2071196-10-4.mol | [Molecular Weight]
473.38 |
| Chemical Properties | Back Directory | [Boiling point ]
468.779±55.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.466±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [pka]
2.573±0.26(predicted) |
| Hazard Information | Back Directory | [Uses]
TQ05310 is an orally available inhibitor of IDH2 mutants, targeting both IDH2-R140Q (IC50=136.9 nM) and IDH2-R172K (IC50=37.9 nM) mutants. TQ05310 inhibits the production of 2-hydroxyglutarate (2-HG) and induces differentiation of cells expressing IDH2-R140Q and IDH2-R172K by inhibiting the enzymatic activity of mutant IDH2. TQ05310 can be used for the study of acute myeloid leukemia[1]. | [IC 50]
IDH2-R140Q: 136.9 nM (IC50); IDH2‐R172K: 37.9 nM (IC50) | [References]
[1] Mingzhao Gao, et al. "Pharmacological characterization of TQ 05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants." Cancer science 110.10 (2019): 3306-3314. DOI:10.1111/cas.14152 |
|
|